The Design of New Integrase Inhibitors Targeting HIV-1

针对 HIV-1 的新型整合酶抑制剂的设计

• 批准号: LP0347088
• 负责人: Prof Paul Keller
• 金额: $ 5.65万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2003
• 资助国家: 澳大利亚
• 起止时间: 2003-04-14 至 2006-04-13
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0347088
• 关键词: Design; New; Integrase; Inhibitors; Targeting

There is still no cure in sight for the worldwide HIV pandemic and the worsening viral resistance problem creates a need to find new and novel compounds for therapeutic use. This project aims to design and synthesize new anti-HIV drugs by targeting two separate enzymes within the HIV life-cycle. This 'dual-action' approach of designing a single molecular scaffold to target separate enzymes would enable a synergistic effect while minimizing development costs. The expected outcomes from this medicinal chemistry project include the discovery of new compounds with the potential for further development as therapeutic agents against HIV.

对于全球范围内的HIV流行病，仍然没有治愈的希望，并且日益恶化的病毒耐药性问题产生了寻找用于治疗用途的新的和新颖的化合物的需要。该项目旨在通过靶向HIV生命周期中的两种不同酶来设计和合成新的抗HIV药物。 这种设计单一分子支架以靶向不同酶的“双重作用”方法将实现协同效应，同时最大限度地降低开发成本。 该药物化学项目的预期成果包括发现新化合物，这些化合物有可能进一步开发为抗艾滋病毒的治疗药物。